Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Metal & pharma, biggest gainers
Wed, 8 Jan 01:30 pm

Indian share markets pared some gains but remained above the dotted line in the post-noon trading session. Barring capital goods and realty, all the sectoral indices are trading in the green with metal, pharma and oil & gas stocks being the biggest gainers.

BSE-Sensex is down 84 points and NSE-Nifty is trading 28 points down. BSE Mid Cap is trading up 0.6% and BSE Small Cap index is trading up 0.2%. The rupee is trading at 62.2 to the US dollar.

Most of the food stocks are trading in the green with Golden Tobacco and Nestle being among major gainers. Agrotech Foods and Sterling Biotech are among the few stocks trading in the red. As per a leading financial daily, Nestle has hiked the price of some its products including instant noodle Maggi, condensed milk Milkmaid and diary whitener EveryDay to pass on rising commodity prices. The company has raised the price of 450 gm of Maggi Hungaroo by 5.5% to Rs 58 whereas the price of 1,000 gm EveryDay dairy whitener was increased by 6.8% to Rs 395. The price of 400 gm Milkmaid has been hiked by 3.4% to Rs 92. Nestle has been battling slow offtake with majority of sales growth coming from better product mix and price-hikes. During 9mCY13, its revenues grew by 10.8%. However, net margin contracted by 0.6% YoY to 12.2% on the back of higher interest and depreciation outgo on expanded capacities and increased provisions for contingencies.

Barring a few almost all pharma stocks are trading firm. Cadila, Dishman Pharma and Cipla are leading among the pack of gainers while Ranbaxy is trading in the red. As per a leading financial daily, Ranbaxy's wholly owned Canadian subsidiary has received approval from Health Canada to manufacture and market RAN Donepezil Hydrochloride tablets. The company would manufacture and sell the tablets in 5 mg and 10 mg dosage. These tablets are used for treatment of dementia in patients suffering from Alzheimer. As per IMS-CDH November 2013 statistics, the total market size of RAN Donepezil Hydrochloride (Aricept) in Canada is estimated at Canadian Dollar (CAD) 153.9 million and is growing at about 38 per cent per annum.

This comes as a positive move for Ranbaxy which has not been able to fetch approvals for its products on time. Further, there have been delays in launch of its products like Diovan. Above all, rising costs to resolve issues over its manufacturing facilities are bigger cause of concern and drag on its profitability.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Metal & pharma, biggest gainers". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.